Guardant Health settles patent disputes over digital sequencing with Foundation Medicine

Foundation Medicine will pay GH$25 million, as well as future royalties for the remainder of the licensed patents for digital sequencing technology.

In turn, GH Foundation Medicine will grant a non-exclusive license to a defined subset of its digital sequencing technology patents.

As a result of this settlement, all pending patent litigation between the 2 firms will be dismissed.

Leave a Comment